A host of China stocks are recommended by investment analysts whether or not the economy gets a boost from measures taken this week to boost the sluggish domestic economy there. On Tuesday, the People's Bank of China announced a series of steps designed to lift the country's slumping economy.
On Sunday, Morgan Stanley analyst Terence Flynn initiated research coverage of the stock with an overweight rating and $118 price target, implying that shares could soar 168%. "Based on Ph1/2a data, we believe GSBR1290's profile is competitive to that of other oral diabesity drugs on the market and in development . We expect Ph2b obesity data for GSBR-1290 by YE25, representing the next catalyst for the program," Flynn wrote.
이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오: